Synergy of Bedaquiline and Capreomycin Against Tuberculosis: In Vitro and In Vivo Efficacy Across Mycobacterium tuberculosis Lineages
Hazem Abdelaal, PhD, SCRI
2024 Keystone Symposia, Tuberculosis: The Host-Pathogen Interface (C4) conference
Tuberculosis (TB) remains the leading cause of death from single infectious agent, surpassing HIV/AIDS and malaria. The alarming emergence of multidrug-resistant (MDR) and extensively drug-resistant Mycobacterium tuberculosis (Mtb) strains presents an urgent need for effective new treatments. Our study aimed to determine the synergistic effects of antibiotic combinations against Mtb.
Impact of Human Immunodeficiency Virus and Peripartum Period on Mycobacterium tuberculosis Infection Detection
Jaclyn Escudero, MPH, UW
Publication, Journal of Infectious Diseases
Pregnancy and human immunodeficiency virus (HIV) may influence tuberculosis infection detection using interferon (IFN)-γ release assay (QFT-Plus; Qiagen) and tuberculin skin test (TST).
Evaluating vaccine-mediated cellular immunogenicity of M72 paired with clinical adjuvants against Mycobacterium tuberculosis in a mouse model
Rakhi Harne, MSc, PhD, SCRI
2024 Keystone Symposia, Tuberculosis: The Host-Pathogen Interface (C4) conference
Mycobacterium tuberculosis (M.tb) is transmitted by the aerosol route from an individual with active pulmonary tuberculosis (TB) and is the leading cause of mortality globally. Although there
has been worldwide effort to develop vaccines against TB the only widely used vaccine is bacillus Calmette–Guérin (BCG), which fails to provide protection against pulmonary TB in adolescents
and adults. Therefore, lead clinical vaccine candidates against TB are urgently required to control the epidemic. The recombinant protein vaccine M72 + AS01E is reported to provide approximately 50% efficacy against TB. These clinical results have led to a renewed enthusiasm in the development of subunit TB vaccines with adjuvants that modulate optimal immunological
responses.
Assessing vaccine-mediated protection in an ultra-low dose Mycobacterium tuberculosis murine model
Courtney Plumlee, PhD, SCRI
2024 Keystone Symposia, Tuberculosis: The Host-Pathogen Interface (C4) conference
Despite widespread immunization with Bacille-Calmette-Guerin (BCG), the only currently licensed tuberculosis (TB) vaccine, TB remains a leading cause of mortality globally. There are many TB vaccine candidates in the developmental pipeline, but the lack of a robust animal model to assess vaccine efficacy has hindered our ability to prioritize candidates for human clinical trials. Here we use a murine ultra-low dose (ULD) Mycobacterium tuberculosis (Mtb) challenge model to assess protection conferred by BCG vaccination.
Preventing tuberculosis with community-based care in an HIV-endemic setting: a modeling analysis
Jennifer Ross, MD, MPH, UW
Union World Conference on Lung Health, 2023
Antiretroviral therapy (ART) and tuberculosis preventive treatment (TPT) both prevent tuberculosis (TB) disease and deaths among people living with HIV. Differentiated care models, including community-based delivery, can increase uptake of ART and TPT in settings with a high burden of HIV-associated TB, particularly among men.
Previous Awardees
Josepha Klas
PacTB, 2023
John Kearney
South Africa based study
Aditi Deshpande, PhD
Gordon Research Conference (Tuberculosis Drug Discovery and Development) at Barcelona, Spain
Danae Black, MPH, UW
Mentor: Dr. LaCourse
Conference on Retroviruses and Opportunistic Infections
Tuberculosis Incidence among Adolescents and Young Adults with HIV in Kenya
Amanda Brumwell MAS, UW
Mentor: Dr. Shapiro
Scoping research on the best practices in clinical care and programmatic management of tuberculosis (TB) and diabetes
Maham Rais, PhD, SCRI
Mentor: Dr. Coler
Keynote Symposia conference, Innate Immunity: From Innate Sensing to Adaptive Responses
Characterizing TLR4 agonist EmT4 as an anti-Mycobacterium tuberculosis vaccine
Steven Makatsa, PhD, UW
Mentor: Dr. Seshadri
Poster Presentation: Keystone Symposia
Mass cytometry reveals diverse cellular and functional phenotypes in broncho alveolar lavage after intravenous BCG vaccination
Hassan Eldesouky, PhD, UW
Mentor: Dr. Sherman
Poster Presentation: Gordon Research Conference
Repurposing FDA-Approved Drugs to Define New Mechanisms of Drug Tolerance in Mycobacterium tuberculosis
Fernanda Rodrigues-Costa, PhD, SCRI
Mentor: Dr. Parish
Poster Presentation: EMBO Workshop on Tuberculosis
Novel Series Kills Mycobacterium tuberculosis in a pH-Dependent Manner